Sugi Predict

Sugi Predict / Compounds / SCHEMBL4246352

SCHEMBL4246352

SCHEMBL4246352

O=C(O)c1ccccc1Nc1cccc([N+](=O)[O-])c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 3/20 0.70
▸ CTSL P07711 3/20 0.70
▸ AKR1C3 P42330 3/20 0.69
▸ AKR1C2 P52895 3/20 0.69
▸ MAPT P10636 4/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ MPO P05164 1/20 0.60
▸ FABP4 P15090 1/20 0.58
▸ CSNK2A1 P68400 1/20 0.58
▸ TAS2R14 Q9NYV8 2/20 0.57
▸ PTGS1 P23219 1/20 0.57
▸ PTGS2 P35354 1/20 0.57
▸ MYC P01106 1/20 0.55
▸ MAX P61244 1/20 0.55
▸ DDX3X O00571 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19657968 0.88 AKR1C3 (0.61) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL10822482 0.87 MAPT (0.65) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL9400915 0.87 AKR1C3 (0.57) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL29779874 0.87 AKR1C3 (0.67) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL4223100 0.85 AKR1C3 (0.67) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL11765925 0.85 MAPT (0.62) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL11762199 0.85 AKR1C3 (0.58) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL1463232 0.85 MEN1 (0.71) MAPTMEN1KMT2ADDX3XPOLB
SCHEMBL4251354 0.84 CTSV (0.71) CTSVCTSLAKR1C3AKR1C2MAPT
SCHEMBL9551973 0.84 CTSV (0.71) CTSVCTSLAKR1C3AKR1C2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150056160-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. 2015-02-26 — — US claimed
CN-103373967-A Synthetic method of shenqinmycin DALIAN JOIN KING BIO CHEMICAL TECHNOLOGY CO LTD 2013-10-30 — — CN claimed
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-05-21 — — US claimed
WO-2007049050-A2 MODULATORS OF GPR40 FOR THE TREATMENT OF DIABETES HEPTAHELIX AB (SE) 2007-05-03 — — WO claimed
EP-1098641-A4 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2003-08-27 — — EP claimed
EP-1098641-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA Texas Pharmaceuticals, Inc. (US) 2001-05-16 — — EP claimed
WO-2000006143-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. (US) 2000-02-10 — — WO claimed
EP-1098641-B1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2016-04-27 — — EP disclosed
US-20150056160-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. 2015-02-26 — — US disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 — — US disclosed
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION CHOUDHARY MUHAMMAD IQBAL (PK) 2015-02-19 — — US disclosed
CN-103373967-A Synthetic method of shenqinmycin DALIAN JOIN KING BIO CHEMICAL TECHNOLOGY CO LTD 2013-10-30 — — CN disclosed
US-20120135864-A1 POLLINATION IMPROVER TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) 2012-05-31 — — US disclosed
WO-1995026632-A1 METHODS FOR USE OF GABAA RECEPTOR GABAergic COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-10-12 — — WO disclosed
EP-0412211-A1 Cancer therapy system THERAPEUTICAL SYSTEMS CORPORATION (US) 1991-02-13 — — EP disclosed
US-4935450-A Cancer therapy system for effecting oncolysis of malignant neoplasms THERAPEUTICAL SYSTEMS CORPORATION (US) 1990-06-19 — — US disclosed
US-4724234-A ADMINISTERING NUTRITIONAL REGIMEN AND AGENTS WHICH UNCOUPLE OXIDATIVE PHOSPHORYLATION THERAPEUTICAL SYSTEMS CORP. (US) 1988-02-09 — — US disclosed
EP-0095641-B1 QUINAZOLINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS Troponwerke GmbH & Co. KG (DE) 1987-07-29 — — EP disclosed
US-4539402-A ANTIINFLAMMATORY AGENTS TROPONWERKE GMBH & CO. (DE) 1985-09-03 — — US disclosed
EP-0095641-A1 Quinazolinone derivatives, process for their preparation and their use in medicaments Troponwerke GmbH & Co. KG (DE) 1983-12-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051286-A1 ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION AGER, NFKBIA, DNPEP CTSV 1340/4885CTSL 970/4885AKR1C3 978/4885
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME CLIC1, ASIC1, CLIC4 CTSV 3420/4885CTSL 3181/4885AKR1C3 787/4885
US-20120135864-A1 POLLINATION IMPROVER AADAT, TIPARP, GSR CTSV 3323/4885CTSL 2623/4885AKR1C3 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.